The Role of Dynamic Contrast-Enhanced Screening Breast MRI in Populations at Increased Risk for Breast Cancer

Breast MRI is more sensitive than mammography in detecting breast cancer. However, MRI as a screening tool is limited to high-risk patients due to cost, low specificity and insufficient evidence for its use in intermediate-risk populations. Nonetheless, in the past decade, there has been a dramatic increase in the use of breast-screening MRI in the community setting. In this review, we set to describe the current literature on the use of screening MRI in high- and intermediate-risk populations. We will also describe novel applications of breast MRI including abbreviated breast MRI protocols, background parenchymal enhancement and diffusion-weighted imaging.

[1]  C. D'Orsi,et al.  Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening , 2006 .

[2]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[3]  Janice S. Sung,et al.  Screening breast MR imaging in women with a history of chest irradiation. , 2011, Radiology.

[4]  Etta D Pisano,et al.  Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. , 2012, JAMA.

[5]  Melissa M. Hudson,et al.  Systematic Review: Surveillance for Breast Cancer in Women Treated With Chest Radiation for Childhood, Adolescent, or Young Adult Cancer , 2010, Annals of Internal Medicine.

[6]  Jennifer D. Brooks,et al.  Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. , 2012, Radiology.

[7]  Jennifer D. Brooks,et al.  The Impact of Bilateral Salpingo-Oophorectomy on Breast MRI Background Parenchymal Enhancement and Fibroglandular Tissue , 2013, European Radiology.

[8]  S. Gavenonis,et al.  Results of MR imaging screening for breast cancer in high-risk patients with lobular carcinoma in situ. , 2011, Radiology.

[9]  H. Bieling,et al.  Accelerated breast MRI for breast cancer screening. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Venter,et al.  The pathology of inherited breast cancer , 2002, Pathology.

[11]  Bruce L Daniel,et al.  Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. , 2006, JAMA.

[12]  S. Cummings,et al.  Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population , 2005, Breast Cancer Research and Treatment.

[13]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[14]  M. Morrow,et al.  Is there a role for routine screening MRI in women with LCIS? , 2013, Breast Cancer Research and Treatment.

[15]  S. Feig,et al.  Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening. , 2010, Radiologic clinics of North America.

[16]  Wendy B DeMartini,et al.  Background parenchymal enhancement on breast MRI: impact on diagnostic performance. , 2012, AJR. American journal of roentgenology.

[17]  Elizabeth A Morris,et al.  Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. , 2011, AJR. American journal of roentgenology.

[18]  Jennifer D. Brooks,et al.  Impact of Tamoxifen on Amount of Fibroglandular Tissue, Background Parenchymal Enhancement, and Cysts on Breast Magnetic Resonance Imaging , 2012, The breast journal.

[19]  Saadallah Ramadan,et al.  Diffusion-weighted imaging of the breast: principles and clinical applications. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[20]  R. Birdwell.  National Trends and Practices in Breast MRI , 2009 .

[21]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  G. Gazelle,et al.  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. , 2010, Radiology.

[23]  R. Warren,et al.  BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials , 2007, Clinical Cancer Research.

[24]  Laura Cortesi,et al.  Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study): Final Results , 2011, Investigative radiology.

[25]  Janice S. Sung,et al.  Screening breast MR imaging in women with a history of lobular carcinoma in situ. , 2011, Radiology.

[26]  T. R. Harrison.  Principles of internal medicine , 1955 .

[27]  Hiroshi Honda,et al.  Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging , 2010, European Radiology.

[28]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Oster,et al.  Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. , 2009, Journal of the American College of Radiology : JACR.

[30]  S. Lorda,et al.  A systematic review of the effectiveness of magnetic resonance imaging ( MRI ) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer , 2007 .

[31]  Alan B Hollingsworth,et al.  An Alternative Approach to Selecting Patients for High‐risk Screening with Breast MRI , 2014, The breast journal.

[32]  Jennifer D. Brooks,et al.  Background parenchymal enhancement at breast MR imaging and breast cancer risk. , 2011, Radiology.

[33]  Sibel Kul,et al.  Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors. , 2011, AJR. American journal of roentgenology.

[34]  P. Brown,et al.  Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[35]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Liberman,et al.  Breast MRI screening of women with a personal history of breast cancer. , 2010, AJR. American journal of roentgenology.

[37]  M. Yaffe,et al.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Narod.  Screening of women at high risk for breast cancer. , 2011, Preventive medicine.

[39]  Kjell Arne Kvistad,et al.  Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. , 2007, Breast.

[40]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[41]  Wendie A Berg,et al.  Tailored supplemental screening for breast cancer: what now and what next? , 2009, AJR. American journal of roentgenology.

[42]  Karla Kerlikowske,et al.  Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. , 2011, JAMA.

[43]  Janet Waters,et al.  MRI for breast cancer screening, diagnosis, and treatment , 2011, The Lancet.

[44]  Jennifer D. Brooks,et al.  Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI , 2012, European Radiology.

[45]  R. Warren,et al.  Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[46]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[47]  E. Halpern,et al.  Cost‐effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers , 2013, Cancer.

[48]  Massimo Bazzocchi,et al.  Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. , 2004, AJR. American journal of roentgenology.

[49]  Rongwei Fu,et al.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation , 2014, Annals of Internal Medicine.

[50]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[51]  Linda Moy,et al.  Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle. , 2013, Radiology.

[52]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[53]  James W Sayre,et al.  National trends and practices in breast MRI. , 2008, AJR. American journal of roentgenology.

[54]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[55]  B. Narin,et al.  Correlation between breast density in mammography and background enhancement in MR mammography , 2010, La radiologia medica.

[56]  S. Heywang-Köbrunner,et al.  Advantages and Disadvantages of Mammography Screening , 2011, Breast Care.

[57]  G. Hortobagyi,et al.  Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer , 2011, Cancer.

[58]  H. Abe,et al.  Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. , 2014, AJR. American journal of roentgenology.

[59]  R. Birdwell,et al.  Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  T. Helbich,et al.  Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? , 2009, Radiology.

[61]  H. Nelson,et al.  Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.

[62]  A R Padhani,et al.  Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer , 2006, British Journal of Cancer.

[63]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[64]  S. Fletcher,et al.  Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011. , 2014, JAMA internal medicine.

[65]  Ammarin Thakkinstian,et al.  Risk prediction models of breast cancer: a systematic review of model performances , 2012, Breast Cancer Research and Treatment.

[66]  Maximilian Reiser,et al.  Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Gatsonis,et al.  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers , 2012, Cancer.

[68]  Andrew N Freedman,et al.  Five-Year and Lifetime Risk of Breast Cancer among U.S. Subpopulations: Implications for Magnetic Resonance Imaging Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[69]  N. Boyd,et al.  Mammographic density and breast cancer risk: current understanding and future prospects , 2011, Breast Cancer Research.

[70]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[71]  Karla Kerlikowske,et al.  Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.

[72]  E. Morris,et al.  Results of MRI Screening for Breast Cancer in High-Risk Patients with LCIS and Atypical Hyperplasia , 2007, Annals of Surgical Oncology.

[73]  P. Skaane,et al.  Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. , 2007, Radiology.

[74]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.